INEX Seeks Approval to Spin-Out Assets Into Tekmira Pharmaceuticals
28-Aug-2006
"We are confident that Tekmira will become a company with all the attributes necessary to take INEX's promising oligonucleotide-based products forward into clinical trials, to work with and benefit from the product development achievements of INEX's existing partners and to build significant value for shareholders," said Timothy M. Ruane, President and Chief Executive Officer of INEX.
Organizations
INEX Pharmaceuticals
Tekmira Pharmaceuticals
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.